ARSA Gene

ARSA Gene

Overview

ARSA (Arylsulfatase A) encodes a lysosomal enzyme essential for the catabolism of sulfatides, a class of sulfated glycolipids that are major components of myelin sheaths in the central and peripheral nervous systems. ARSA deficiency causes metachromatic leukodystrophy (MLD), a progressive hereditary leukodystrophy characterized by white matter destruction, demyelination, and progressive neurological deterioration [@gieselmann1994].

The ARSA gene is located on chromosome 22q13.33 and encodes a 511-amino acid protein that is synthesized as a preproenzyme and processed to the mature form in the lysosome. The enzyme catalyzes the hydrolysis of cerebroside-3-sulfate (sulfatide) to cerebroside, an essential step in the degradative pathway of myelin lipids [@polten1991].

ARSA Gene

Overview

ARSA (Arylsulfatase A) encodes a lysosomal enzyme essential for the catabolism of sulfatides, a class of sulfated glycolipids that are major components of myelin sheaths in the central and peripheral nervous systems. ARSA deficiency causes metachromatic leukodystrophy (MLD), a progressive hereditary leukodystrophy characterized by white matter destruction, demyelination, and progressive neurological deterioration [@gieselmann1994].

The ARSA gene is located on chromosome 22q13.33 and encodes a 511-amino acid protein that is synthesized as a preproenzyme and processed to the mature form in the lysosome. The enzyme catalyzes the hydrolysis of cerebroside-3-sulfate (sulfatide) to cerebroside, an essential step in the degradative pathway of myelin lipids [@polten1991].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">ARSA Gene — Arylsulfatase A</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ARSA</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>22q13.33</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P15289" target="_blank">P15289</a></td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>410</td></tr>
<tr><td><strong>Protein Length</strong></td><td>511 amino acids</td></tr>
<tr><td><strong>EC Number</strong></td><td>3.1.6.8</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Sulfatase family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/melanoma" style="color:#ef9a9a">Melanoma</a>, <a href="/wiki/senescence" style="color:#ef9a9a">Senescence</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">27 edges</a></td>
</tr>
</table>
</div>

Molecular Biology

Gene Structure

The ARSA gene spans approximately 3.2 kb and consists of 8 exons encoding the mature enzyme. The coding sequence is highly conserved across species, reflecting the critical role of ARSA in normal CNS development and function.

Protein Structure and Function

Arylsulfatase A is a secreted glycoprotein that localizes to the lysosome. The enzyme:

• Requires a unique formylglycine (FG) cofactor at position 71 for catalytic activity
• Forms a homodimer in its active form
• Has optimal activity at acidic pH (4.5-5.5)
• Catalyzes the hydrolysis of sulfatide in the lysosome

Sulfatide Metabolism

Sulfatides are among the most abundant lipids in myelin, constituting up to 15% of total lipid content. Normal sulfatide catabolism:

Expression Pattern

Tissue Distribution

ARSA is expressed in:

• Oligodendrocytes (highest) — primary source in CNS, essential for myelin maintenance
• [Neurons](/entities/neurons) (moderate) — important for neuronal function
• [Astrocytes](/entities/astrocytes) — supporting cells in CNS
• Schwann cells — peripheral nervous system myelination
• Peripheral tissues — kidney, liver, pancreas, lung, spleen

Brain Region Specificity

Expression data from the [Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=ARSA) shows highest ARSA expression in:

• White matter (oligodendrocyte-rich regions)
• Corpus callosum — major white matter tract
• Cerebral cortex (layer 5 pyramidal neurons)
• Hippocampus (CA1-3 regions)
• Cerebellar white matter

Metachromatic Leukodystrophy (MLD)

Epidemiology

• Incidence: 1 in 40,000 to 1 in 160,000 live births
• Inheritance: Autosomal recessive
• Ethnic variation: Higher in certain populations (e.g., Israeli Arab, Western European)
• Carrier frequency: ~1 in 60-150 in general population

Clinical Forms

MLD manifests in three main forms based on age of onset:

Late-Infantile Form (60-70% of cases)

• Onset: 1-2 years of age
• Progression: Most severe form, rapid deterioration
• Features: Motor regression, ataxia, hypotonia, peripheral neuropathy, optic atrophy
• Prognosis: Death within 5-10 years without treatment

Juvenile Form (20-30% of cases)

• Onset: 3-10 years of age
• Progression: Intermediate rate of decline
• Features: Behavioral changes, cognitive decline, motor difficulties, seizures
• Prognosis: Progressive disability over 10-20 years

Adult Form (5-10% of cases)

• Onset: Adolescence to adulthood (15-40 years)
• Progression: Slowest progression, can span decades
• Features: Psychiatric symptoms, cognitive decline, motor impairment
• Prognosis: Variable, may have normal lifespan with progressive disability

Pathophysiology

The cascade of events in MLD:

Key Pathogenic Mechanisms:

Diagnosis

Clinical Diagnosis

• Neurological examination: Motor regression, ataxia, signs of neuropathy
• Family history: Consanguinity, affected siblings

Laboratory Testing

• ARSA enzyme activity: Reduced in leukocytes or fibroblasts (0-10% of normal)
• Sulfatide levels: Elevated in urine, CSF, or tissue
• Neuroimaging: MRI shows characteristic white matter changes
• Nerve conduction studies: Demyelinating peripheral neuropathy

Genetic Testing

• ARSA sequencing: Identifies pathogenic variants
• Prenatal testing: Available for at-risk pregnancies
• Carrier testing: For at-risk family members

Neuroimaging Features

MRI characteristics of MLD include[@khan2020][@van der Knaap2018]:

• Diffuse cerebral white matter abnormalities: T2 hyperintensity, particularly in periventricular regions
• Differential involvement: Early sparing of U-fibers, later involvement
• Tigroid pattern: Striped appearance on T2-weighted images
• Cerebellar white matter involvement: Often prominent
• Progressive atrophy: Brain volume loss over time
• Cortical involvement: Late-stage involvement of gray matter

ARSA Mutations and Genotype-Phenotype Correlation

Mutation Spectrum

Over 250 pathogenic variants have been identified in the ARSA gene[@franchini2012][@cesani2016]:

• Missense mutations: Most common (~60%)
• Splice-site mutations: ~20%
• Nonsense mutations: ~10%
• Small deletions/insertions: ~5%
• Large deletions: Rare

Common Pathogenic Variants

| Variant | Type | Frequency | Clinical Impact |
|---------|------|-----------|-----------------|
| c.454T>C (p.P152R) | Missense | Common (European) | Severe |
| c.526C>T (p.Q176X) | Nonsense | Common | Severe |
| c.1009C>T (p.R337X) | Nonsense | Common | Severe |
| c.915+1G>A | Splice | Variable | Variable |
| c.1044+1G>A | Splice | Variable | Variable |

Genotype-Phenotype Correlation

Genotype strongly influences phenotype[@cesani2019]:

• Null mutations (nonsense, frameshift): Late-infantile form
• Missense mutations with residual activity: Juvenile or adult form
• Partial activity variants: Later onset, slower progression

Pseudodeficiency

Pseudoarylsulfatase deficiency is a common benign polymorphism characterized by:

• Reduced ARSA activity (10-15% of normal) in healthy individuals
• c.3A>G (p.P2P) and c.1055A>G (p.D352G) variants
• Normal sulfatide metabolism in vivo
• No clinical consequences
• Important for diagnosis: Can confound enzymatic testing

Therapeutic Approaches

Gene Therapy — Libmeldy (Atidarsagene Autotemcel)

Libmeldy is the first approved gene therapy for MLD[@rugieri2020][@kragl2022]:

• Mechanism: Autologous hematopoietic stem cells transduced with lentiviral vector encoding functional ARSA
• Administration: Single intravenous infusion after conditioning
• Outcomes: Stabilization or improvement in 90%+ of treated patients
• Long-term data: Sustained benefit up to 8+ years post-treatment

• Early-treated patients: 100% survival, 77% free of severe motor impairment
• Treated before symptom onset: Best outcomes
• Late-treated: Variable benefit depending on disease stage

Hematopoietic Stem Cell Transplantation (HSCT)

• Allogeneic HSCT: Can stabilize disease progression
• Timing critical: Best outcomes when performed presymptomatically or early
• Mixed outcomes: Variable depending on donor match, conditioning, timing
• Replaced by gene therapy in many centers

Enzyme Replacement Therapy (ERT)

Currently under development[@barENDS2023]:

• Recombinant ARSA: PEGylated for improved delivery
• Intravenously administered: Weekly or biweekly
• Clinical trials: Ongoing for safety and efficacy
• Challenges: Blood-brain barrier penetration

Substrate Reduction Therapy

Emerging approaches targeting sulfatide synthesis:

• Myelin inhibition: Reduce sulfatide production
• Small molecule approaches: Under preclinical investigation
• Combination approaches: ERT + substrate reduction

Supportive Care

• Physical therapy: Maintain mobility, prevent contractures
• Occupational therapy: Adaptive equipment, daily activities
• Speech therapy: For dysarthria and communication
• Nutritional support: For feeding difficulties
• Seizure management: Antiepileptic medications as needed
• Orthopedic interventions: For contractures and scoliosis

Connection to Neurodegenerative Diseases

While MLD is primarily a pediatric leukodystrophy, ARSA and sulfatide metabolism have relevance to broader neurodegeneration research:

Oligodendrocyte Function

• Sulfatides are essential for myelin stability
• Oligodendrocyte dysfunction implicated in multiple sclerosis and other demyelinating conditions
• ARSA deficiency provides a model for studying oligodendrocyte survival

Lipid Metabolism and Neurodegeneration

• Abnormal lipid metabolism is a feature of AD, PD, and other neurodegenerative diseases
• Sulfatide alterations have been reported in AD brain
• Lysosomal dysfunction is a common theme across neurodegeneration

Gene Therapy Platform

• Lentiviral vector approaches developed for MLD inform other gene therapy applications
• CNS gene delivery strategies have broader applicability

Animal Models

Several animal models exist for MLD:

• ARSA knockout mouse: Sulfatide accumulation, progressive demyelination
• ARSA-deficient dog: More severe phenotype, model for therapy testing
• Zebrafish model: For high-throughput drug screening

Research Directions

Current Research Focus

Clinical Trials

• Libmeldy trials: Long-term follow-up, expanded access
• ERT trials: Safety and efficacy studies
• Natural history studies: Better understanding of disease progression

Cross-Links

• [Metachromatic Leukodystrophy](/diseases/metachromatic-leukodystrophy) — Disease page
• [Libmeldy Gene Therapy](/therapeutics/libmeldy-gene-therapy) — Treatment page
• [Oligodendrocyte](/cell-types/oligodendrocyte) — Myelin-producing cells
• [Myelin](/entities/myelin) — White matter structure
• [Leukodystrophies](/diseases/leukodystrophies-overview) — Related disorders
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders) — Disease category

External Links

• [OMIM: ARSA](https://omim.org/entry/607143)
• [UniProt P15289](https://www.uniprot.org/uniprot/P15289)
• [GeneReviews: Metachromatic Leukodystrophy](https://www.ncbi.nlm.nih.gov/books/NBK1130/)
• [MLD Foundation](https://www.mldfoundation.org/)
• [ClinicalTrials.gov: MLD](https://clinicaltrials.gov/search?cond=metachromatic+leukodystrophy)

References